Brought to you by:
Walking can relieve leg pain in people with PAD
Exercise can play an important role in treating peripheral arterial disease (PAD), a recent review by Amy Harwood, PhD, from the Centre for Sport and Exercise Life Sciences at Coventry University and the faculty of health sciences at the University of…
Target 2021: SVS councils and committees drill down on key goals for year ahead (Part 2)
While there is little doubt the pandemic has impacted each vascular surgeon and the SVS as a Society in numerous ways, the commitment and dedication of SVS committee, council and task force members to deliver on the mission has remained…
‘Successful’ first-in-human use of the Efemoral scaffold system announced
Efemoral Medical has announced the first-in-human (FIH) use of the company’s Efemoral Vascular scaffold system (EVSS) with FlexStepv technology in the EFEMORAL I FIH clinical study. The medical device company said the technology offers a new approach to treat peripheral…
WIfI score found to be accurate across racial groups
The wound, ischemia and foot infection (WIfI) score is as accurate a predictor of risk for limb loss in Black people as it is among whites, an SVS Foundation-supported study found. The research on patients with chronic limb-threatening ischemia (CLTI)…
Revascularization ‘improves’ walking performance in claudicating PAD patients
Revascularization of the lower extremity improves hemodynamics, walking performance, quality of life and calf-muscle pathology in claudicating patients with peripheral arterial disease (PAD), researchers in Nebraska found. Furthermore, baseline systolic pressure in the foot, at 15 seconds after relief of…
VOYAGER PAD: Rivaroxaban plus aspirin versus aspirin alone among CLTI patients undergoing revascularization reduced risk of adverse outcomes at three years
In one of the latest sub-analyses from the VOYAGER PAD trial, investigators found that rivaroxaban plus aspirin versus aspirin alone in the high-risk population of patients with critical limb-threatening ischemia (CLTI) undergoing lower-extremity revascularization reduced the risk of a first…
Previously described patient-centered clinical success measure after revascularization for diabetic foot wounds may be ‘too strict’
Patient-centered clinical success after lower-extremity revascularization for people with diabetic foot wounds was achieved among 63% of patients in a new analysis—but researchers suggest the measure on which the study was based may define clinical success too strictly given the…
Intravascular lithotripsy ‘superior’ to PTA in acute procedural success out to 30 days
The DISRUPT PAD III randomized controlled trial (RCT) provides the largest level-one evidence for the treatment of heavily calcified femoropopliteal arteries, noted William Gray, MD, an interventional cardiologist at Main Line Health, Philadelphia, during the second and final late-breaking data…
Latest VOYAGER PAD analysis finds no mortality and improved limb outcomes in drug-coated device cohort
Given the absence of a safety signal in data from the VOYAGER PAD trial, a new analysis examined the potential benefit of drug-coated device versus non-drug-coated device treatment for reducing limb outcomes. Connie Hess, MD, an associate professor of cardiology…
Utilize new SVS Branding Toolkit
The new SVS Branding Toolkit—a robust set of tools designed to help members communicate their roles in comprehensive vascular care—is now available exclusively and at no cost to members of the Society for Vascular Surgery (SVS). Additionally, most are customizable…